Patents Assigned to Acerta Pharma B.V.
  • METHODS OF BLOCKING THE CXCR-4/SDF-1 SIGNALING PATHWAY WITH INHIBITORS OF BRUTON'S TYROSINE KINASE
    Publication number: 20170035756
    Abstract: In some embodiments, the present invention relates to novel small molecule inhibitors that block the CXCR4-SDF-1 signaling pathway by directly inhibiting members of the Tec family of kinases, namely Bruton's tyrosine kinase (BTK), and their use in treating diseases in which pathogenesis is mediated by the CXCR4/SDF-1 signaling pathway.
    Type: Application
    Filed: April 10, 2015
    Publication date: February 9, 2017
    Applicant: Acerta Pharma B.V.
    Inventors: Raquel IZUMI, Francisco SALVA, Ahmed HAMDY
  • Bruton's tyrosine kinase inhibitors for hematopoietic mobilization
    Patent number: 9522917
    Abstract: Methods to improve hematopoiesis and increase white blood cell counts in subjects and patients using pyrimidine-based inhibitors of Bruton's tyrosine kinase (Btk) are disclosed.
    Type: Grant
    Filed: April 11, 2013
    Date of Patent: December 20, 2016
    Assignee: Acerta Pharma B.V.
    Inventors: Raquel Izumi, Francisco Salva, Ahmed Hamdy